Investors - Press Releases
Tabula Rasa Healthcare to Sell DoseMeRx
"At our last earnings call, we noted that we were evaluating options to unlock value in non-core assets. This strategic divestiture underscores TRHC's commitment to sharpening our focus on our core mission, better positioning the company for growth and increased shareholder value," said TRHC Chairman and CEO,
DoseMeRx is an advanced precision dosing tool to help physicians and pharmacists accurately dose patients' high-risk medications based on individual needs, reducing risk, and improving patient outcomes.
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give current expectations or forecasts of future events or the Company's future financial or operating performance, and include the Company's expectations regarding healthcare regulations, industry trends, available opportunities to the Company, the financial and operating performance of the Company, the impacts of the COVID-19 pandemic, and the Company's expectations for 2022 and beyond. Such statements are identified by use of the words "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "should," and similar expressions. These forward-looking statements are based on management's good-faith expectations, judgements, and assumptions as of the date of this Report. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the impacts of the ongoing COVID-19 pandemic and other health epidemics; fluctuations in the Company's financial results; the acceptance and use of the Company's products and services by PACE organizations; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable governmental regulations; the Company's ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing the Company's growth effectively; the Company's ability to adequately protect its intellectual property; the requirements of being a public company; the Company's ability to recognize the expected benefits from acquisitions on a timely basis or at all; and the other risk factors set forth from time to time in the Company's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/tabula-rasa-healthcare-to-sell-dosemerx-301478115.html
TRHC Media Contact: Anthony Mirenda, firstname.lastname@example.org, 908-380-2143; TRHC Investors: Frank Sparacino, email@example.com, 866.648.2767